Risk Prediction Equations for Atherosclerotic CVD Perform Similarly by Race – HealthDay
A new study reveals that risk prediction equations for atherosclerotic cardiovascular disease (ASCVD) are consistent across races but show gender …
» Read moreA new study reveals that risk prediction equations for atherosclerotic cardiovascular disease (ASCVD) are consistent across races but show gender …
» Read moreThe point here isn’t to suggest that being a Crossfit enthusiast or running half marathons isn’t wonderful for your physical health if that’s what you …
» Read morea new study suggests lung cancer screening is riskier for patients in routine clinical practice compared to those who took part in the NLST.
» Read moreShe even entered some web pages to talk, to read about alternative treatments. I haven’t accepted that yet. But hey, right now… I’m receiving …
» Read moreThese drugs, known as GLP-1 receptor agonists, are approved to treat diabetes or weight loss. They include semaglutide, branded as Ozempic, Rybelsus …
» Read moreAdvair (fluticasone propionate/salmeterol) is a brand-name inhaled drug prescribed for asthma and chronic obstructive pulmonary disease (COPD) in …
» Read moreFor coronary heart disease (CHD) incidence, replacing processed meat with nuts showed a lower risk, but the evidence was low for other substitutions.
» Read moreThe fact is that beyond just physical benefits, like weight loss and improved cardiovascular health, physical exercise also yields more intangible …
» Read moreA study found a connection between pregnancy weight and certain blood markers in women with gestational diabetes.
» Read moreDuring the podcast, the actress and her doctor emphasized the importance of finding the right protocol for each cancer patient. Dr. Piro noted that …
» Read moreSector Alternative Medicine. 1st Jan change, Capi. AION THERAPEUTIC INC. Stock Aion Therapeutic Inc. 0.00%, 3 M $. SHIJIAZHUANG YILING PHARMACEUTICAL …
» Read more… COPD thErapy”) for COPD maintenance treatment. Ensifentrine met the primary endpoint in both ENHANCE-1 and ENHANCE-2 trials demonstrating …
» Read more